

Press Release

Abliva AB (publ), 556595-6538
09 February 2023 08:30:00 CET - Lund,
Sweden



Abliva Announces Issuance of a New U.S. Patent for Therapeutic Compound NV354

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the granting of a composition of matter patent for the NV354 compound by the U.S. Patent and Trademark Office. The patent further strengthens Abliva's intellectual property position and coverage for the drug candidate NV354, data for which is currently being assembled for clinical trial applications that will facilitate a future Phase 1 start.

On January 31, 2023, the patent "Succinate Prodrug, Compositions Containing the Succinate Prodrug and Uses Thereof" was issued by the U.S. Patent Court as Patent No 11,565,998. The patent covers isolated forms of NV354. This patent provides an important layer of protection for NV354 in addition to previously granted patents for a broader group of NV354-related compounds.

"The granting of this composition of matter patent for NV354 in the U.S. is an important event as it provides additional protection to NV354, which will become increasingly important as we move this compound into clinical development. It also demonstrates our strong commitment to intellectual property at Abliva, ensuring protection of both scientific innovation as well as commercial opportunity for our pipeline of assets", said Ellen Donnelly, CEO. "Abliva has always had a keen focus on the protection of our assets and the pursuit of robust claims in granted patents across the globe."

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: <https://abliva.com/posts/news-subscription/>

Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>

Subscribe to our YouTube channel: <https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg>

Press Release

Abliva AB (publ), 556595-6538
09 February 2023 08:30:00 CET - Lund,
Sweden



Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of mitochondrial diseases. These rare and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

[Abliva Announces Issuance of a New U.S. Patent for Therapeutic Compound NV354](#)